Home
/
MADRIGAL PHARMACEUTICALS, INC.
/
Financials
/
Quarterly
MADRIGAL PHARMACEUTICALS, INC. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that MADRIGAL PHARMACEUTICALS, INC. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2025
Mar 31, 2025
$137.25M
May 1, 2025
Q1
2025
Mar 31, 2024
$0
May 1, 2025
Q3
2024
Sep 30, 2023
$0
Oct 31, 2024
Q2
2024
Jun 30, 2023
$0
Aug 7, 2024
Q1
2024
Mar 31, 2023
$0
May 7, 2024
Q3
2021
Sep 30, 2021
$0
Nov 4, 2021
Q2
2021
Jun 30, 2021
$0
Aug 5, 2021
Q1
2021
Mar 31, 2021
$0
May 6, 2021
Q3
2021
Sep 30, 2020
$0
Nov 4, 2021
Q2
2021
Jun 30, 2020
$0
Aug 5, 2021
Q3
2020
Sep 30, 2019
$0
Nov 5, 2020
Q2
2020
Jun 30, 2019
$0
Aug 6, 2020
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$287.27M
Nov 4, 2025
Q2
2025
Jun 30, 2025
$212.80M
Aug 5, 2025
Q1
2025
Mar 31, 2025
$137.25M
May 1, 2025
Q3
2025
Sep 30, 2024
$62.18M
Nov 4, 2025
Q2
2025
Jun 30, 2024
$14.64M
Aug 5, 2025
Q1
2025
Mar 31, 2024
$0
May 1, 2025
Q3
2024
Sep 30, 2023
$0
Oct 31, 2024
Q2
2024
Jun 30, 2023
$0
Aug 7, 2024
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($114.19M)
Nov 4, 2025
Q2
2025
Jun 30, 2025
($42.28M)
Aug 5, 2025
Q3
2025
Jun 30, 2025
($42.28M)
Nov 4, 2025
Q3
2025
Mar 31, 2025
($73.24M)
Nov 4, 2025
Q1
2025
Mar 31, 2025
($73.24M)
May 1, 2025
Q2
2025
Mar 31, 2025
($73.24M)
Aug 5, 2025
Q3
2025
Sep 30, 2024
($106.96M)
Nov 4, 2025
Q2
2025
Jun 30, 2024
($151.97M)
Aug 5, 2025
Q3
2025
Jun 30, 2024
($151.97M)
Nov 4, 2025
Q3
2025
Mar 31, 2024
($147.54M)
Nov 4, 2025
Q1
2025
Mar 31, 2024
($147.54M)
May 1, 2025
Q2
2025
Mar 31, 2024
($147.54M)
Aug 5, 2025
Q3
2024
Sep 30, 2023
($98.74M)
Oct 31, 2024
Q2
2024
Jun 30, 2023
($85.80M)
Aug 7, 2024
Q3
2024
Jun 30, 2023
($85.80M)
Oct 31, 2024
Q2
2024
Mar 31, 2023
($76.90M)
Aug 7, 2024
Q3
2024
Mar 31, 2023
($76.90M)
Oct 31, 2024
Q1
2024
Mar 31, 2023
($76.90M)
May 7, 2024
Q3
2023
Sep 30, 2022
($81.20M)
Nov 6, 2023
Q3
2023
Jun 30, 2022
($70.73M)
Nov 6, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($113.98M)
Nov 4, 2025
Q2
2025
Jun 30, 2025
($47.20M)
Aug 5, 2025
Q1
2025
Mar 31, 2025
($79.31M)
May 1, 2025
Q3
2025
Sep 30, 2024
($116.30M)
Nov 4, 2025
Q2
2025
Jun 30, 2024
($162.54M)
Aug 5, 2025
Q1
2025
Mar 31, 2024
($152.04M)
May 1, 2025
Q3
2024
Sep 30, 2023
($98.53M)
Oct 31, 2024
Q2
2024
Jun 30, 2023
($86.45M)
Aug 7, 2024
Q1
2024
Mar 31, 2023
($78.34M)
May 7, 2024
Q3
2023
Sep 30, 2022
($80.41M)
Nov 6, 2023
Q2
2023
Jun 30, 2022
($70.27M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($57.59M)
May 9, 2023
Q3
2022
Sep 30, 2021
($63.16M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
($61.74M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($52.98M)
May 9, 2022
Q3
2021
Sep 30, 2020
($58.79M)
Nov 4, 2021
Q2
2021
Jun 30, 2020
($50.33M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($38.01M)
May 6, 2021
Q3
2020
Sep 30, 2019
($24.20M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($22.70M)
Aug 6, 2020